-
1. Caplacizumab - Wikipedia
Link: https://en.wikipedia.org:443/wiki/Caplacizumab
Description: WEBCaplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura (TTP) and thrombosis. This drug was developed by Ablynx NV.
-
2. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
Link: https://www.nejm.org:443/doi/full/10.1056/NEJMoa1806311
Description: WEBJan 9, 2019 · Caplacizumab, a humanized, bivalent, variable-domain-only immunoglobulin fragment (Nanobody, Ablynx), targets the A1 domain of von Willebrand factor, preventing interaction with the platelet...
-
3. Caplacizumab: Uses, Interactions, Mechanism of Action
Link: https://go.drugbank.com:443/drugs/DB06081
Description: WEBNov 18, 2007 · Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP). Caplacizumab: Uses, Interactions, Mechanism of Action | DrugBank Online
-
4. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Link: https://www.nejm.org:443/doi/full/10.1056/NEJMoa1505533
Description: WEBFeb 11, 2016 · Caplacizumab, an anti–von Willebrand factor humanized single-variable-domain immunoglobulin (Nanobody), inhibits the interaction between ultralarge von Willebrand factor multimers and platelets.
-
5. Caplacizumab Uses, Side Effects & Warnings - Drugs.com
Link: https://www.drugs.com:443/mtm/caplacizumab.html
Description: WEBMay 1, 2023 · What is caplacizumab? Caplacizumab is used to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Caplacizumab is given together with immunosuppressant medication and plasma exchange (transfusion). Caplacizumab may also be used for purposes not listed in this medication guide.
-
6. caplacizumab: Uses, Taking, Side Effects, Warnings - Medicine.com
Link: https://www.medicine.com:443/drug/caplacizumab
Description: WEBFeb 25, 2020 · Caplacizumab is used to treat acquired thrombotic thrombocytopenic purpura (aTTP). Before taking caplacizumab, tell your doctor: If you are allergic to caplacizumab; any part of this medicine; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had.
-
7. Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
Link: https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC8017799/
Description: WEBDec 2, 2021 · Caplacizumab is a novel agent approved for the treatment of adult patients with aTTP in conjunction with plasma exchange and immunosuppressive therapies. It works by binding to the A1 domain of von Willebrand factor (VWF), blocking platelets from binding to VWF and aggregating.
-
8. Caplacizumab (Cablivi) - NCBI Bookshelf - National Center for
Link: https://www.ncbi.nlm.nih.gov:443/books/NBK596632/
Description: WEBCaplacizumab has been approved by Health Canada for the treatment of adults with aTTP in combination with PE and IST. Caplacizumab is a bivalent humanized nanobody and an antithrombotic drug and platelet aggregation inhibitor.
-
9. Caplacizumab: First Global Approval - PMC - National Center for
Link: https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC6280848/
Description: WEBOct 8, 2018 · Caplacizumab (Cablivi™), a humanised single-variable-domain immunoglobulin (Nanobody ®) targeting von Willebrand factor, has been developed by Ablynx, a Sanofi Company, for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
-
10. Caplacizumab-yhdp - NCI - National Cancer Institute
Link: https://www.cancer.gov:443/about-cancer/treatment/drugs/caplacizumab-yhdp
Description: WEBCancer Treatment. A to Z List of Cancer Drugs. Caplacizumab-yhdp. (KAP-luh-SIH-zoo-mab) This page contains brief information about caplacizumab-yhdp and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. US Brand Name (s) Cablivi. FDA Approved. Yes.